GLENDALE, Calif., March 5, 2018 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (NASDAQ:AMEH), an integrated population health management company focused on value-based care, and 42 Interactive, Inc. ("42i") (formerly Helynx, Inc.), a technology company that has developed a next-generation machine learning and data discovery platform, today
The conference, which takes place from March 7-9 at the Langham Huntington Hotel in Pasadena, California, gathers world-renowned experts, including speakers from Harvard Medical School, MIT, IBM Watson Health, Imperial College London and Taipei Medical University. ApolloMed and 42i's study, "Artificial Intelligence Techniques for Improved Prediction of Adverse Health Events", used 42i's analytics engine to predict emergency department visits and hospital admissions on 30,000 patients in ApolloMed's accountable care organization ("ACO").
The study was carried out by Chess Stetson, Ph.D., Boris Revechkis, Ph.D., and Kris Chaisanguantham, Ph.D. from 42i and Diane Pham, M.D. from ApolloMed. Dr. Stetson will be presenting the study on March 8th at 5:20pm just prior to the conference gala dinner.
"ApolloMed has been at the forefront of the intersection of artificial intelligence and healthcare. Our collaboration with Dr. Stetson and his team at 42i began in 2015 and continues to produce important insights for us," stated Warren Hosseinion, M.D., Co-Chief Executive Officer of Apollo Medical Holdings. "We plan on expanding our efforts in this space and will be dedicating more people and resources from the data analytics and IT teams at Network Medical Management, our management services organization."
"Machine learning, combined with expert clinical knowledge, can provide completely new insights into improving patient care and reducing the cost of care," stated Chess Stetson, Ph.D., Chief Executive Officer of 42i, Inc. "Our goal is to help ApolloMed prevent avoidable adverse outcomes for its patients."
About Apollo Medical Holdings, Inc. (ApolloMed)
ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization ("NGACO"), and its affiliated Independent Physician Associations (each, an "IPA"), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner. Led by a management team with over two decades of experience, ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes: Network Medical Management (MSO), Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (Next Generation ACO), ApolloMed ACO (MSSP Accountable Care Organization), Allied Physicians of California (IPA), Maverick Medical Group (IPA), Apollo Care Connect (Digital Population Health Management Platform) and ApolloMed Palliative Care Services (Hospice/Palliative Care and Home Health Care). ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net.
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the success and continuity of the Company's relationship with Accountable IPA and the Company's population health management platform. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, associated with such statements, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company and its subsidiaries and variable interest entities to be materially different than those that may be anticipated on the basis of historical trends. Examples of such risks and uncertainties include but are not limited to the impact of emerging and existing competitors, the effect of new legislation on the Company's industry and business, the effectiveness of the Company's compliance and control initiatives, changes to Medicare reimbursement programs, whether or not the Company receives an "all or nothing" annual payment from the CMS in connection with our participation in the Medicare Shared Savings Program (the "MSSP"); the success of the Company's focus on next generation accountable care organization ("NGACO"), including whether the Company can continue to participate in the All-Inclusive Population-Based Payment ("AIPBP") Mechanism of the NGACO Model, as well as other factors described from time to time in the Company's reports to the Securities and Exchange Commission (including without limitation the "Risk Factors" discussed in the Company's Quarterly Report on Form 10-Q filed on November 14, 2017 for the quarter ended September 30, 2017, Annual Report on Form 10-K filed on June 29, 2017 for the year ended March 31, 2017, Registration Statement Amendment No. 2 on Form S-4/A filed on November 9, 2017, and Rule 424(b)(3) prospectus filed on November 15, 2017). Should one or more of these risks or uncertainties materialize, or should any expectations or assumptions underlying the relevant forward-looking statements prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in such statements as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Investors and other readers, therefore, should not place reliance on any forward-looking statements or use any historical trends to anticipate or predicate results or trends in future periods. Any statements included herein are made only as of the date hereof. The Company undertakes no obligation to update or revise any statement to reflect the impact of circumstances or events that arise after the date hereof, except as required by law, and also undertakes no obligation to correct or update information prepared by third parties.
FOR MORE INFORMATION, PLEASE CONTACT:
Gary AugustaPresidentApollo Medical Holdings(818) firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/apollomed-and-42-interactive-to-present-results-of-predictive-analytics-study-at-the-1st-international-conference-on-artificial-intelligence-in-healthcare-300607902.html
SOURCE Apollo Medical Holdings, Inc.
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All